Literature DB >> 11425776

Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice.

Y Zhu1, P M Farrehi, W P Fay.   

Abstract

BACKGROUND: Plasminogen activator inhibitor type 1 (PAI-1) inhibits neointima formation after vascular injury. Hyperlipidemia modulates the expression of multiple genes, however, and the effects of PAI-1 on the arterial response to injury under hyperlipidemic conditions are unknown. The purpose of this study was to examine the impact of PAI-1 on intimal hyperplasia and other vascular changes that develop after arterial injury in apolipoprotein E-deficient (apoE(-/-)) mice. METHODS AND
RESULTS: Ferric chloride injury of the midportion of the common carotid arteries of apoE(-/-) mice (n=22) induced formation of a neointima that contained smooth muscle cells, foam cells, neutral lipid, tissue factor, and von Willebrand factor. Interactions between vascular injury and apolipoprotein E deficiency were strongly synergistic; either stimulus alone was insufficient to induce significant neointima formation. Mean intima/media ratios were significantly greater (P<0.03) in apoE(-/-), PAI-1(+/+) mice (5.6+/-1.8, n=12) than in apoE(-/-), PAI-1(-/-) mice (1.2+/-0.55, n=12), as were the percentages of bromodeoxyuridine-positive cells in the intima and media (P<0.03). Transiently occlusive (<48 hours) and nonocclusive mural thrombi persisted longer in apoE(-/-), PAI-1(+/+) mice than in apoE(-/-), PAI-1(-/-) mice.
CONCLUSIONS: In atherosclerosis-prone mice, PAI-1 promotes neointima formation after oxidative vascular injury. The apparent hyperlipidemia-dependent effect of PAI-1 may be mediated by its capacity to inhibit the clearance of platelet-fibrin thrombi that can deliver growth factors to the blood vessel wall or be incorporated into developing vascular lesions. Alternatively, hyperlipidemia may alter the pattern of gene expression in the blood vessel wall to enhance potential effects of PAI-1 on antiproliferative processes, such as transforming growth factor-beta activation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425776     DOI: 10.1161/01.cir.103.25.3105

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

1.  A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.

Authors:  Yoshiyuki Morishima; Yuko Honda
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

Review 2.  Applied gene therapy in preclinical models of vascular injury.

Authors:  Stefan P Janssens
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

3.  Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia.

Authors:  Jianbo Wu; Lin Peng; Grainne A McMahon; Daniel A Lawrence; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-02       Impact factor: 8.311

4.  Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.

Authors:  Yan Ji; Zhen Weng; Philip Fish; Neha Goyal; Mao Luo; Samantha P Myears; Tammy L Strawn; Bysani Chandrasekar; Jianbo Wu; William P Fay
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-09-22       Impact factor: 8.311

Review 5.  The hemostasis system in murine atherosclerosis.

Authors:  Takayuki Iwaki; Victoria A Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2008-03       Impact factor: 3.465

Review 6.  Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.

Authors:  Rohan Samarakoon; Paul J Higgins
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

7.  The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque.

Authors:  Mary Drinane; Jessica Mollmark; Lyubomir Zagorchev; Karen Moodie; Baiming Sun; Amy Hall; Samantha Shipman; Peter Morganelli; Michael Simons; Mary Jo Mulligan-Kehoe
Journal:  Circ Res       Date:  2009-01-02       Impact factor: 17.367

8.  Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.

Authors:  Tessa M Simone; Paul J Higgins
Journal:  Mol Med Ther       Date:  2012-08-05

9.  Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.

Authors:  A T Obi; J A Diaz; N L Ballard-Lipka; K J Roelofs; D M Farris; D A Lawrence; T W Wakefield; P K Henke
Journal:  J Thromb Haemost       Date:  2014-07-23       Impact factor: 5.824

Review 10.  Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.

Authors:  Susanne Trost; Richard Pratley; Burton Sobel
Journal:  Curr Diab Rep       Date:  2006-02       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.